JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS

JPMorgan Chase & Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 260.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 171,941 shares of the company’s stock after buying an additional 124,287 shares during the quarter. JPMorgan Chase & Co. owned 0.56% of Keros Therapeutics worth $2,720,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in KROS. Tudor Investment Corp ET AL purchased a new stake in Keros Therapeutics during the 3rd quarter valued at $309,000. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Keros Therapeutics by 15.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 607,089 shares of the company’s stock valued at $9,604,000 after purchasing an additional 82,749 shares in the last quarter. Sherbrooke Park Advisers LLC purchased a new stake in shares of Keros Therapeutics during the third quarter valued at $176,000. Qube Research & Technologies Ltd increased its holdings in Keros Therapeutics by 683.7% in the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock worth $4,795,000 after buying an additional 264,445 shares in the last quarter. Finally, Public Employees Retirement System of Ohio raised its position in Keros Therapeutics by 58.8% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 41,453 shares of the company’s stock worth $656,000 after buying an additional 15,350 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $12.00 on Monday. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $22.55. The company has a market capitalization of $236.64 million, a P/E ratio of 6.59 and a beta of 0.98. The stock’s 50-day moving average price is $14.23 and its 200-day moving average price is $16.47.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.37). Keros Therapeutics had a net margin of 35.65% and a return on equity of 14.25%. The company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $3.66 million. During the same quarter last year, the firm posted ($1.14) earnings per share. The company’s revenue was down 87.2% compared to the same quarter last year. Research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on KROS shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. TD Cowen upgraded shares of Keros Therapeutics to a “hold” rating in a research note on Friday, December 19th. Wells Fargo & Company lowered their price target on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Finally, Zacks Research lowered Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Keros Therapeutics currently has an average rating of “Hold” and a consensus price target of $21.86.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.